💪 Clinical prediction starts with the right cellular models.

janvier 20, 2026

Patient cells transformed by CYTOO's MyoScreen™ become screening platforms that anticipate therapeutic success in the clinic.

🎯 Our key advantages:

✓ Physiologically relevant disease markers

✓ Multi-modal molecular analyses (RT-qPCR, RNA-seq, omics)

✓ Quantitative therapeutic rescue measurement

Real-world example with DM1: our models faithfully replicate DMPK RNA foci, MBNL1 dysregulation, splicing abnormalities, and calcium signaling disruptions.

💊 Powering multiple partnerships spanning gene therapies, small molecules, and oligonucleotides.

Inherited diseases or muscular dystrophies – CYTOO provides the robust models essential for pharma development.

Want to test your therapeutic candidate in authentic disease conditions? Contact us!

Microscopic pretzels that could be a game-changer in drug discovery. 🥨🔬

No, this isn’t a random metaphor.

When acetylcholine receptors (AChR) organize on the surface of a myotube, they form pretzel-like structures – exactly as they

🔬 Autophagy in Skeletal Muscle: Detect it. Quantify it. Target it.

Autophagy is a critical quality-control mechanism that clears damaged proteins and organelles from muscle cells. Autophagy dysregulation plays a role in disease pathogenesis — yet

DM1: what if the problem isn’t just in the muscles?

Myotonic Dystrophy type 1 (DM1) is the most common muscular dystrophy in adults. It has long been considered a muscle-only disorder. A study published in

💪 Clinical prediction starts with the right cellular models.

Share:

More Posts

Microscopic pretzels that could be a game-changer in drug discovery. 🥨🔬

🔬 Autophagy in Skeletal Muscle: Detect it. Quantify it. Target it.

DM1: what if the problem isn’t just in the muscles?

Join us on LinkedIn

Contact us